Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CRPOF NYSE:IBIO OTCMKTS:ICOTF OTCMKTS:NVLNF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRPOFCeapro$0.17$0.17$0.11▼$0.40$13.31M1.4715,466 shsN/AIBIOiBio$0.66-3.1%$0.80$0.64▼$6.89$10.89M0.941.45 million shs371,327 shsICOTFiCo Therapeutics$0.39-3.7%$0.37$0.80▼$1.82$3.50M2.034,760 shs51,500 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRPOFCeapro0.00%0.00%0.00%0.00%0.00%IBIOiBio-3.09%-10.11%-10.95%-34.75%-67.85%ICOTFiCo Therapeutics-2.45%-4.40%-22.64%-14.03%+13.37%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRPOFCeaproN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.288 of 5 stars3.50.00.00.00.60.00.6ICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRPOFCeapro 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00658.73% UpsideICOTFiCo Therapeutics 0.00N/AN/AN/ANVLNFNovelion Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ICOTF, NVLNF, CRPOF, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRPOFCeapro$7.14M1.86$0.06 per share2.74$0.32 per share0.53IBIOiBio$375K29.03N/AN/A$1.41 per share0.47ICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ANVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRPOFCeapro-$3.49M-$0.06N/A∞N/A-69.60%-20.30%-18.07%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ANVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRPOFCeaproN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRPOFCeaproN/A11.007.72IBIOiBio0.051.761.76ICOTFiCo TherapeuticsN/A0.720.72NVLNFNovelion TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRPOFCeaproN/AIBIOiBio7.90%ICOTFiCo TherapeuticsN/ANVLNFNovelion Therapeutics48.64%Insider OwnershipCompanyInsider OwnershipCRPOFCeaproN/AIBIOiBio0.58%ICOTFiCo TherapeuticsN/ANVLNFNovelion Therapeutics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRPOFCeaproN/A78.29 millionN/ANot OptionableIBIOiBio10016.52 million9.82 millionN/AICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableNVLNFNovelion Therapeutics10919.62 millionN/ANot OptionableICOTF, NVLNF, CRPOF, and IBIO HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeICOTF, NVLNF, CRPOF, and IBIO Company DescriptionsCeapro OTCMKTS:CRPOF$0.17 0.00 (0.00%) As of 06/6/2024Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.iBio NYSE:IBIO$0.66 -0.02 (-3.09%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.66 0.00 (-0.61%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Novelion Therapeutics OTCMKTS:NVLNF$0.70 -0.01 (-1.20%) As of 01/16/2020Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
